Clinical Trials Logo

Clinical Trial Summary

Study to evaluate patient preference of deferasirox FCT or deferasirox DT in patient with transfusion - dependent thalassemia or non-transfusion -dependent thalassemia as measured by preference questionnaire at Week 48

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

  • Non-transfusion-dependent Thalassemia
  • Thalassemia
  • Transfusion-dependent Thalassemia

NCT number NCT02993224
Study type Interventional
Source Novartis
Status Completed
Phase Phase 2
Start date July 27, 2017
Completion date March 11, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT04718844 - A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT04364269 - Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of VIT-2763 in β-thalassaemia Phase 2
Withdrawn NCT04176653 - Study in Beta-thalassaemia or Myelodysplastic Syndrome Patients to Investigate the Safety and Tolerability of SLN124 Phase 1